Skip to content
value.today

Icosavax, Inc.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2017
Total raised
$130 M
2 rounds on record
Latest round
$100 M
Mar 2021
First round on record
Aug 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Icosavax, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$100 MNo. 2$50 to $250 million

Icosavax, Inc.: Raise no. 2, Mar 2021

Investors in this round

36 investors had bought by the notice of Apr 7, 2021: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Icosavax, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam K. Simpson · Director, Executive Officer · President and Chief Executive Officer
  • Cassia A. Cearley · Executive Officer · Treasurer, Chief Business Officer
  • Charles A. Richardson · Executive Officer · Senior Vice President, Technical Operations
  • Douglas A. Holtzman · Executive Officer · Chief Scientific Officer and Secretary
  • Niranjan A. Kanesa-thasan · Executive Officer · Chief Medical Officer
  • Eric A. Moessinger · Director
  • Jason A. Hafler · Director
  • Mark A. McDade · Director
  • Peter A. Kolchinsky · Director
  • Tadataka Yamada, M.D. · Director · Chairman of the Board
  • Terry A. Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Adam K. Simpson, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 7, 2021. Read the notice at the SEC.

equitySEC
Aug 2019$30 MNo. 1$10 to $50 million

Icosavax, Inc.: Raise no. 1, Aug 2019

Investors in this round

22 investors had bought by the notice of Oct 18, 2019: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for Icosavax, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $51 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam K. Simpson · Executive Officer, Director · President and Chief Executive Officer
  • Charles A. Richardson · Executive Officer · Senior Vice President, Technical Operations
  • Douglas A. Holtzman · Executive Officer · Chief Scientific Officer, Treasurer and Secretary
  • Niranjan A. Kanesa-thasan · Executive Officer · Chief Medical Officer
  • Eric A. Moessinger · Director
  • Jason A. Hafler · Director
  • Mark A. McDade · Director
  • Tadataka Yamada, M.D. · Director · Chairman of the Board
  • Terry A. Gould · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Adam K.Simpson, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 18, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Icosavax, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2021).

    SEC Form D · Apr 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2021

That is all the official record says: Icosavax, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in Icosavax, Inc.
InvestorKindAmountRoundRoleSource
Adams Street Partners LLCFund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NanoDimension III GP Limited PartnershipFund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NanoDimension III, L.P.Fund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
NanoDimension III Management LtdFund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Qiming U.S. Healthcare Fund II, L.P.Fund or asset managernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Qiming U.S. Healthcare GP II, LLCOthernot statednot statedHeld Series A-1 and B-1 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
RA Capital Healthcare Fund LPFund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Ra Capital Management, L.P.Fund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
RA Capital Nexus Fund II, L.P.Fund or asset managernot statednot statedHeld Series B-1 preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Icosavax, Inc.
NameRoleNamed in
Adam K. SimpsonPresident and Chief Executive OfficerApr 2021
Cassia A. CearleyTreasurer, Chief Business OfficerApr 2021
Charles A. RichardsonSenior Vice President, Technical OperationsApr 2021
Douglas A. HoltzmanChief Scientific Officer and SecretaryApr 2021
Niranjan A. Kanesa-thasanChief Medical OfficerApr 2021
Adam K. SimpsonPresident and Chief Executive OfficerApr 2021
Eric A. MoessingerDirectorApr 2021
Jason A. HaflerDirectorApr 2021
Mark A. McDadeDirectorApr 2021
Peter A. KolchinskyDirectorApr 2021
Tadataka Yamada, M.D.Chairman of the BoardApr 2021
Terry A. GouldDirectorApr 2021